cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ionis Pharmaceuticals Inc
4 own
25 watching
Current Price
$40.92
$-0.28
(-0.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,811.35M
52-Week High
52-Week High
48.82
52-Week Low
52-Week Low
29.676
Average Volume
Average Volume
0.59M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
106.6829
iconMarket Capitalization5,811.35M
icon52-Week High48.82
icon52-Week Low29.676
iconAverage Volume0.59M
iconDividend Yield--
iconP/E Ratio106.6829
What does the Ionis Pharmaceuticals Inc do?
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...
Read More
How much money does Ionis Pharmaceuticals Inc make?
News & Events about Ionis Pharmaceuticals Inc.
Zolmax
10days ago
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price objective upped by SVB Leerink from $32.00 to $33.00 in a research note issued to investors on Monday, Benzinga reports. SVB Leerink currently has a market perform rating on the stock. SVB Leerink also issued estimates for Ionis ...
Zolmax
10days ago
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price objective upped by SVB Leerink from $32.00 to $33.00 in a research note issued to investors on Monday, Benzinga reports. SVB Leerink currently has a market perform rating on the stock. SVB Leerink also issued estimates for Ionis ...
PR Newswire
10days ago
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research PR...
Zolmax
14days ago
Ionis Pharmaceuticals (NASDAQ:IONS Get Rating) had its price target boosted by Piper Sandler from $60.00 to $62.00 in a report published on Thursday, The Fly reports. They currently have an overweight rating on the stock. Other analysts also recently issued reports about the stock. SVB Leerink ...
Benzinga
17days ago
Latest Ratings for IONS DateFirmActionFromTo Mar 2022GuggenheimInitiates Coverage OnBuy Mar 2022CitigroupInitiates Coverage OnSell Feb 2022SVB LeerinkMaintainsMarket Perform View More Analyst Ratings for IONS View the Latest Analyst Ratings read more...
Frequently Asked Questions
Frequently Asked Questions
What is Ionis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Ionis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Ionis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Ionis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ionis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ionis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$40.92
$-0.28
(-0.68%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00